The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Defective Gp130-Mediated Signal Transducer and Activator of Transcription (Stat) Signaling Results in Degenerative Joint Disease, Gastrointestinal Ulceration, and Failure of Uterine Implantation
Open accessAbstract
The receptor subunit gp130 transduces multiple cell type–specific activities of the leukemia inhibitory factor (LIF)/interleukin (IL)-6 family of cytokines through the signal transducer and activator of transcription (STAT) and src homology 2 domain–bearing protein tyrosine phosphatase (SHP)-2/ras/Erk pathways. To define STAT-dependent physiological responses, we generated mice with a COOH-terminal gp130ΔSTAT “knock-in” mutation which deleted all STAT-binding sites. gp130ΔSTAT mice phenocopyed mice deficient for IL-6 (impaired humoral and mucosal immune and hepatic acute phase responses) and LIF (failure of blastocyst implantation). However, unlike mice with null mutations in any of the components in the gp130 signaling pathway, gp130ΔSTAT mice also displayed gastrointestinal ulceration and a severe joint disease with features of chronic synovitis, cartilaginous metaplasia, and degradation of the articular cartilage. Mitogenic hyperresponsiveness of synovial cells to the LIF/IL-6 family of cyto-kines was caused by sustained gp130-mediated SHP-2/ras/Erk activation due to impaired STAT-mediated induction of suppressor of cytokine signaling (SOCS) proteins which normally limits gp130 signaling. Therefore, the joint pathology in gp130ΔSTAT mice is likely to arise from the disturbance of the otherwise balanced activation of the SHP-2/ras/Erk and STAT signaling cascades emanating from gp130.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 Hyperresponsiveness of synovial cells correlates with sustained Erk MAPK activation. (A) [3H]thymidine incorporation by synovial cells prepared from wt and gp130ΔSTAT/ΔSTAT mice and stimulated with LIF or IL-6. Cells derived from clinically unaffected joints were stimulated for 24 h with the indicated concentration of LIF or IL-6 in the presence of sIL-6R (500 ng/ml). Each point represents the mean ± SD. *P < 0.05 compared with unstimulated cultures of the same genotype. (B) Activation of intermediate signaling molecules in synovial cells stimulated with IL-6 and sIL-6R (both at 500 ng/ml) for the indicated period of time. Cell lysates were immunoprecipitated with either a Jak-2 antiserum and incubated with γ-[32P]ATP to assess Jak-2 autophosphorylation, or with a SHP-2 antiserum and blotted with antiphosphotyrosine antibodies. Erk MAPK activation was analyzed by directly probing lysates with an antibody specific for phospho-Erk1/2 (Erk-P). The total amount of SHP-2 and Erk proteins was assessed by reprobing the membranes for SHP-2 and Erk1/2, respectively.](/paper-figures/cf639907011d4f18ae744c9dbe66d06e/defective-gp130-mediated-signal-transducer-and-activator-of-transcription-stat-figure-6.jpg)

![Figure 8 Impaired SOCS induction enhances IL-6 and LIF responsiveness. (A) Mitogenic hyperresponsiveness of SOCS-1–deficient synovial cells to IL-6. [3H]thymidine incorporation assays were carried out on primary cultures of syonvial cells, derived from mice of the indicated genotype, in the presence of the indicated concentration of IL-6 and sIL-6R (500 ng/ml) as described in the legend to Fig. 5 a. Each point represents the mean ± SD. *P < 0.05 compared with unstimulated cultures of the same genotype. (B) SOCS-1–deficient cells show sustained activation of Erk1/2 in response to IL-6. Erk MAPK phosphorylation assay of synovial fibroblasts stimulated for the indicated time with IL-6 and sIL-6R (both at 500 ng/ml) as described in Fig. 5 b. Erk1/2-P indicates the phosphorylated isoforms of Erk1 and Erk2. The total amount of Erk protein was assessed by reprobing the membranes for Erk1/2. (C) Hyperresponsiveness of synovial cells to IL-6 is corrected by overexpressing SOCS-1. Synovial cells were transiently transfected with a fos-luc reporter construct, the Srα-β-gal control plasmid and increasing concentrations of a Flag-epitope tagged SOCS-1 (pSOCS-1) expression construct, stimulated for 48 h with human IL-6 plus sIL-6R (both at 500 ng/ml) or 10% FCS as a positive control. Luciferase activity was normalized by reference to β-galactosidase activity and is expressed as fold induction over unstimulated cultures. The level of SOCS-1Flag protein was assessed at the end of the experiment by immunoprecipitation and Western blotting using anti-Flag antibodies. Each point represents the mean ± SD.](/paper-figures/1259989a23914c739819ab49fc9e7267/defective-gp130-mediated-signal-transducer-and-activator-of-transcription-stat-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, defective STAT3 activation enhances SHP-2–ERK–MAPK activation pathways, most likely through an impaired STAT3-mediated induction of suppressor of cytokine signaling 3 (SOCS3) (111, 112).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [111]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
Self-citationBlastocyst implantation depends on maternal expression of leukaemia inhibitory factor
Stewart, C. L., Kašpar, P., Brunet, L. J., Bhatt, H., Gadi, I. K., Köntgen, F., & Abbondanzo, S. J. (1992) · Nature · doi:10.1038/359076a0 · Cited by 2,033
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.
Dalton, D., Pitts-Meek, S., Keshav, S., Figari, I., Bradley, A., & Stewart, T. (1993) · Science · doi:10.1126/science.8456300 · Cited by 2,015
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 4×
“Since the phenotype of gp130FxxQ/FxxQ mice is somewhat reminiscent of that observed in LIF-R / (10) and CNTF-R / mice (36), but entirely different to that associated with IL-6 / (4, 5) or IL-11R 1 / mice (8, 9), signaling through the heterodimeric LIF-R /gp130 rather than through homodimeric gp130 appears critical aft…”
BackgroundInfluentialSelf-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3.Preprint
Niwa, H., Burdon, T., Chambers, I., & Smith, A. G. (1998) · Genes & Development · doi:10.1101/gad.12.13.2048 · Cited by 1,673
Kelley, W. N. (1985) · Virtual Defense Library (Ministerio de Defensa) · Cited by 1,641
gp 130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES
Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,468
Structure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040
Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979
Research works printed but not linked: 1
- Waring, 1997, Leukemia inhibitory factor, 467
Cited by
Sorted by citations
Kaser, A., Zeissig, S., & Blumberg, R. S. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101225 · Cited by 1,806
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
Roadmap to embryo implantation: clues from mouse models
Wang, H., & Dey, S. K. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1808 · Cited by 1,324
Cyclic Decidualization of the Human Endometrium in Reproductive Health and Failure
Gellersen, B., & Brosens, J. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1045 · Cited by 1,176
Molecular Cues to Implantation
Dey, S. K., Lim, H. J., Das, S. K., Reese, J., Paria, B. C., Daikoku, T., & Wang, H. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0020 · Cited by 1,120
Metadata
- Authors
- Ernst, M., Inglese, M., Waring, P., Campbell, I. K., Bao, S., Clay, F. J., Alexander, W. S., Wicks, I. P., Tarlinton, D. M., Novak, U., Heath, J. K., & Dunn, A. R.
- Affiliations
- The Royal Melbourne Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- The University of Sydney (AU)
- The University of Melbourne (AU)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2001-07-16
- Volume
- 194
- Issue
- 2
- Pages
- 189-204
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2193459
- OpenAlex
- W2125415295
- Cited by
- 227
- References
- 51
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 1 · 2017: 8 · 2016: 4 · 2015: 5 · 2014: 8 · 2013: 12 · 2012: 6
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Keywords
- gp130, STAT signaling, interleukin-6, suppressor of cytokine signaling, articular cartilage degeneration, synovitis, gastrointestinal ulceration, embryo implantation, cytokine receptor signaling, knock-in mice
- MeSH terms
- Suppressor of Cytokine Signaling 1 Protein, Animals, Carrier Proteins, DNA-Binding Proteins, Female, Joint Diseases, Male, Membrane Glycoproteins, Mice, Mutant Strains, Embryo Implantation, Peptic Ulcer, Pregnancy, Repressor Proteins, Signal Transduction, Trans-Activators, Antigens, CD, DNA Primers, Mice, Knockout, Mitogen-Activated Protein Kinases, STAT1 Transcription Factor, STAT3 Transcription Factor, Cytokine Receptor gp130, Suppressor of Cytokine Signaling Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review